Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 20/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 1/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | MMP3 | P08254 | 1/20 | 0.76 |
| ▸ | MMP2 | P08253 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL6429390 | 0.99 | BMP1 (0.98) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6428262 | 0.88 | BMP1 (0.78) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL27567224 | 0.88 | BMP1 (0.78) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6428360 | 0.88 | BMP1 (1.00) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5408264 | 0.87 | BMP1 (0.78) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6429362 | 0.87 | BMP1 (1.00) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6428452 | 0.87 | BMP1 (1.00) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6428730 | 0.86 | BMP1 (0.82) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14502749 | 0.86 | BMP1 (1.00) | BMP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5404106 | 0.86 | BMP1 (1.00) | BMP1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608977-A1 | COMPOSITIONS AND METHODS FOR ACCELERATED PRODUCTION OF THYMIC CELLS FROM PLURIPOTENT STEM CELLS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-09-03 | — | — | EP | claimed |
| CN-119162082-A | Method for preparing extrahepatic vesicles/apoptotic vesicles by inducing fibroblasts to be directly reprogrammed into liver-like cells and application of method | 中国人民解放军海军军医大学 | 2024-12-20 | — | — | CN | claimed |
| CN-118308295-B | Additive, culture medium and method for promoting cell to produce collagen | 上海遇见味来生物技术有限公司 | 2024-08-27 | — | — | CN | claimed |
| CN-118308295-A | Additive, culture medium and method for promoting cell to produce collagen | 上海遇见味来生物技术有限公司 | 2024-07-09 | — | — | CN | claimed |
| WO-2024091676-A1 | COMPOSITIONS AND METHODS FOR ACCELERATED PRODUCTION OF THYMIC CELLS FROM PLURIPOTENT STEM CELLS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-05-02 | — | — | WO | claimed |
| WO-2023221565-A1 | METHOD FOR DIFFERENTIATING INDUCED PLURIPOTENT STEM CELL INTO PANCREATIC ISLET AND USE THEREOF IN TREATING TYPE I DIABETES MELLITUS | 呈诺再生医学科技(北京)有限公司 | 2023-11-23 | — | — | WO | claimed |
| CN-115838684-B | In-vitro accurate simulation method for pulmonary fibrosis | 淇嘉科技(天津)有限公司 | 2023-05-12 | — | — | CN | claimed |
| CN-115786245-A | Method for constructing human bionic lung organoid | 淇嘉科技(天津)有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-114836369-A | Method for differentiating induced pluripotent stem cells into pancreatic islets and application of induced pluripotent stem cells in treatment of type I diabetes | 呈诺再生医学科技(北京)有限公司 | 2022-08-02 | — | — | CN | claimed |
| CN-114807015-A | Induction method for promoting islet alpha cells to be converted into beta cells and application thereof | 呈诺再生医学科技(北京)有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-108721282-B | Application of UK383367 in preparation of medicine for relieving renal fibrosis related diseases | 南京市儿童医院 | 2022-02-15 | — | — | CN | claimed |
| EP-1240152-B1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-08 | — | — | EP | claimed |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | BAILEY SIMON (US) | 2003-06-26 | — | — | US | claimed |
| JP-2003519133-A | — | — | 2003-06-17 | — | — | JP | claimed |
| CN-1423638-A | Oxazolyl hydroxamic acids as procollagen C-protease inhibitors | PFIZER LTD (US) | 2003-06-11 | — | — | CN | claimed |
| EP-1240152-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2002-09-18 | — | — | EP | claimed |
| US-6448278-B2 | ANTISCARRING AGENT | PFIZER INC. | 2002-09-10 | — | — | US | claimed |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | PFIZER INC. | 2001-09-13 | — | — | US | claimed |
| WO-2001047901-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2001-07-05 | — | — | WO | claimed |
| US-20250382580-A1 | COMPOSITIONS AND METHODS FOR ACCELERATED PRODUCTION OF THYMIC CELLS FROM PLURIPOTENT STEM CELLS | UNIV COLORADO REGENTS (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4608977-A1 | COMPOSITIONS AND METHODS FOR ACCELERATED PRODUCTION OF THYMIC CELLS FROM PLURIPOTENT STEM CELLS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-09-03 | — | — | EP | disclosed |
| CN-120082503-A | Liver progenitor organoid culture medium and culture method | 成都艾名迈德医学检验实验室有限公司 | 2025-06-03 | — | — | CN | disclosed |
| WO-2025059227-A1 | COMPOSITIONS AND METHODS FOR GENERATING AND USING PATIENT-SPECIFIC THYMUS-BEARING MICE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-119162082-A | Method for preparing extrahepatic vesicles/apoptotic vesicles by inducing fibroblasts to be directly reprogrammed into liver-like cells and application of method | 中国人民解放军海军军医大学 | 2024-12-20 | — | — | CN | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| CN-118308295-B | Additive, culture medium and method for promoting cell to produce collagen | 上海遇见味来生物技术有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-118308295-A | Additive, culture medium and method for promoting cell to produce collagen | 上海遇见味来生物技术有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024091485-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PULMONARY FIBROSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024091676-A1 | COMPOSITIONS AND METHODS FOR ACCELERATED PRODUCTION OF THYMIC CELLS FROM PLURIPOTENT STEM CELLS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-2968536-B1 | METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY | US HEALTH (US) | 2023-06-28 | — | — | EP | disclosed |
| CN-115786245-B | Human bionic lung organoid construction method | 淇嘉科技(天津)有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-115838684-B | In-vitro accurate simulation method for pulmonary fibrosis | 淇嘉科技(天津)有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-115786244-B | Screening process of anti-pulmonary fibrosis drug effect | 淇嘉科技(天津)有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115772492-B | Method for constructing pulmonary fibrosis disease model in vitro by using bleomycin | 淇嘉科技(天津)有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115838684-A | In-vitro accurate simulation method for pulmonary fibrosis | 淇嘉科技(天津)有限公司 | 2023-03-24 | — | — | CN | disclosed |
| CN-115786245-A | Method for constructing human bionic lung organoid | 淇嘉科技(天津)有限公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-115786244-A | Anti-pulmonary fibrosis drug effect screening process | 淇嘉科技(天津)有限公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-115772492-A | Method for constructing pulmonary fibrosis disease model in vitro by using bleomycin | 淇嘉科技(天津)有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-114836369-B | Method for differentiating induced pluripotent stem cells into pancreatic islets and application of induced pluripotent stem cells in treatment of type I diabetes | 呈诺再生医学科技(北京)有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-114807015-B | Induction method for promoting islet alpha cells to be converted into beta cells and application thereof | 呈诺再生医学科技(北京)有限公司 | 2022-11-22 | — | — | CN | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| CN-114836369-A | Method for differentiating induced pluripotent stem cells into pancreatic islets and application of induced pluripotent stem cells in treatment of type I diabetes | 呈诺再生医学科技(北京)有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114807015-A | Induction method for promoting islet alpha cells to be converted into beta cells and application thereof | 呈诺再生医学科技(北京)有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20220184111-A1 | METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2022-06-16 | — | — | US | disclosed |
| US-11285169-B2 | Methods for modulating chemotherapeutic cytotoxicity | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-03-29 | — | — | US | disclosed |
| CN-108721282-B | Application of UK383367 in preparation of medicine for relieving renal fibrosis related diseases | 南京市儿童医院 | 2022-02-15 | — | — | CN | disclosed |
| CN-108721282-B | Application of UK383367 in preparation of medicine for relieving renal fibrosis related diseases | 南京市儿童医院 | 2022-02-15 | — | — | CN | disclosed |
| CN-108721282-B | Application of UK383367 in preparation of medicine for relieving renal fibrosis related diseases | 南京市儿童医院 | 2022-02-15 | — | — | CN | disclosed |
| US-6897306-B2 | 3-heterocyclylpropanohydroxamic acids | PFIZER PRODUCTS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1240152-B1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | BAILEY SIMON (US) | 2003-06-26 | — | — | US | disclosed |
| CN-1423638-A | Oxazolyl hydroxamic acids as procollagen C-protease inhibitors | PFIZER LTD (US) | 2003-06-11 | — | — | CN | disclosed |
| EP-1240152-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| US-6448278-B2 | ANTISCARRING AGENT | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | PFIZER INC. | 2001-09-13 | — | — | US | disclosed |
| WO-2001047901-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001047901-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | MMP1, CTSL, PREP | BMP1 166/4885PDE4A 2310/4885PDE4B 3399/4885 |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | CPA1, MMP1, PREP | BMP1 79/4885PDE4A 1831/4885PDE4B 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.